Filing Details

Accession Number:
0001123292-25-000081
Form Type:
13G Filing
Publication Date:
2025-02-12 19:00:00
Filed By:
GILEAD SCIENCES INC
Company:
Ikena Oncology Inc.
Filing Date:
2025-02-13
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
GILEAD SCIENCES INC 0 1,521,312 3.6%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The numbers reported in rows 5, 7, and 9 reflect the Reporting Person's beneficial ownership as of February 11, 2025. The percent reported in row 11 is calculated based on 42,042,645 shares of common stock, par value $0.001 per share, of the Issuer ("Common Stock"), which excludes 6,215,466 shares of non-voting Common Stock, outstanding as of November 1, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.


SCHEDULE 13G


 
GILEAD SCIENCES INC
 
Signature:/s/ Andrew Dickinson
Name/Title:Andrew Dickinson, Chief Financial Officer
Date:02/13/2025